Crossmark

Pharmacokinetics, safety, and tolerability of four 28-day cycle intramuscular injections for risperidone-ISM 75 mg in patients with schizophrenia: A phase-2 randomized study (PRISMA-2)

Crossref DOI link: https://doi.org/10.1016/j.eurpsy.2016.01.605

Published Online: 2020-03-23

Published Print: 2016-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Anta, L.

Llaudó, J.

Ayani, I.

Gorostidi, B.

Monreal, M.

Martínez-González, J.

Ochoa, L.

Gutierro, I.
License Information

License valid from 2020-03-23

Text and Data Mining valid from 2016-03-01
More Information

This article is maintained by: Elsevier

Article Title: Pharmacokinetics, safety, and tolerability of four 28-day cycle intramuscular injections for risperidone-ISM 75 mg in patients with schizophrenia: A phase-2 randomized study (PRISMA-2)

Journal Title: European Psychiatry

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eurpsy.2016.01.605

Content Type: simple-article

Copyright: Copyright © 2016 Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below